Researcher's surprising finding could lead to glanders vaccine

October 19, 2012
Results from this western blot analysis suggest that B. thailandensis ATPK01 (lane 5) contains immunogens that would generate protective immunity against B. mallei infection.

(Medical Xpress)—Apichai Tuanyok dedicated several years to working on a bacterial pathogen in Canada, but his breakthrough occurred in Flagstaff with an unexpected finding on a routine lab report.

Although the Tuanyok is investigating at Northern Arizona University is closely related to, but not the same, as the one he had researched in Canada, the results felt like a payoff for all the effort.

"I emailed many people that day," Tuanyok said, recalling his excitement at the lab report filed by his graduate student. What Tuanyok wrote in the email was that he possibly had found a vaccine target for glanders, a severe infectious disease that is usually limited to horses and donkeys but has potential as a biowarfare agent.  

Follow-up tests at NAU's Center for and Genomics (MGGen), where Tuanyok is an assistant research professor of biological sciences, have convinced Tuanyok that "we have the right target, but we have to identify further what bacterial species would be a good candidate" for an effective vaccine.

What Tuanyok found was that a common known as ATPK 1 plays a role in generating against glanders infection, with a 70 percent survival rate among infected .

Glanders, caused by the bacterium Burkholderia mallei, occurs in several countries in the Middle East, Mediterranean and South America. Human infection is uncommon but when it occurs, the bacterium is highly antibiotic resistant. No vaccine currently exists.

The Department of Defense has taken an interest because the bacterium, in aerosolized form, could be used as a bioweapon. During the , it is believed that Germany used methods to spread glanders intentionally, infecting Russian horses and mules used by the military. It was also used by the Japanese in .

Tuanyok is working on a manuscript with Paul Keim, NAU Regents' professor and director of MGGen, to describe the research and hopefully generate more funding.

It was Keim, in fact, who brought Tuanyok to the MGGen lab based on his work with melioidosis, a tropical disease that claims thousands of lives each year in Tuanyok's native Thailand. The bacterium behind that disease, Burkholderia pseudomallei, was still Tuanyok's focus when he first arrived at NAU in 2006. He may yet return to it.

"The vaccine we're working on may not be used for another disease," Tuanyok said, "but I have another idea for melioidosis and I may be able to do some work in parallel."

Explore further: Anthrax capsule vaccine protects monkeys from lethal infection

Related Stories

Anthrax capsule vaccine protects monkeys from lethal infection

January 12, 2012
a naturally occurring component of the bacterium that causes the disease—protected monkeys from lethal anthrax infection, according to U.S. Army scientists. The study, which appears in the Jan. 20th print edition of ...

Recommended for you

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Scientists identify biomarkers that indicate likelihood of survival in infected patients

November 17, 2017
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease.

Research team unlocks secrets of Ebola

November 16, 2017
In a comprehensive and complex molecular study of blood samples from Ebola patients in Sierra Leone, published today (Nov. 16, 2017) in Cell Host and Microbe, a scientific team led by the University of Wisconsin-Madison has ...

Study raises possibility of naturally acquired immunity against Zika virus

November 16, 2017
Birth defects in babies born infected with Zika virus remain a major health concern. Now, scientists suggest the possibility that some women in high-risk Zika regions may already be protected and not know it.

A structural clue to attacking malaria's 'Achilles heel'

November 16, 2017
Researchers from The Scripps Research Institute (TSRI) and PATH's Malaria Vaccine Initiative (MVI) have shed light on how the human immune system recognizes the malaria parasite though investigation of antibodies generated ...

Molecular pathway offers treatment targets for pulmonary fibrosis, related conditions

November 15, 2017
A study led by investigators at Massachusetts General Hospital (MGH) and University Health Network (UHN) in Toronto has identified a molecular pathway that appears to be critical to the development of fibrosis - scarring ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.